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Abstract
Introduction Gene expression analysis is used to subtype
breast cancers such that the most aggressive tumors are
identified, but translating this into clinical practice can be
cumbersome. Our goal is to develop a universal biomarker that
distinguishes patients at high risk across all breast cancer
subtypes. We previously reported that Y-box binding protein-1
(YB-1), a transcription/translation factor, was a marker of poor
prognosis in a cohort of 490 patients with breast cancer, but the
study was not large enough to subtype the cancers. We
therefore investigated whether YB-1 identifies patients at risk for
either reduced relapse free survival or decreased r breast
cancer specific survival (BCSS) across all tumor subtypes by
evaluating 4,049 cases.
Methods Tumor tissue microarrays, representing 4,049 cases
of invasive breast cancers with 20 years of follow up, were
subtyped by the expression profiles of estrogen receptor,
progesterone receptor, or HER-2. We then addressed whether
YB-1 expression identified patients at higher risk for relapse
and/or lower BCSS.
Results We found YB-1 to be a highly predictive biomarker of
relapse (P < 2.5 × 10-20) and poor survival (P < 7.3 × 10-26) in
the entire cohort and across all breast cancer subtypes. Patients
with node-positive or node-negative cancer were more likely to
die from the disease if YB-1 was expressed. This was further
substantiated using a Cox regression model, which revealed
that it was significantly associated with relapse and poor survival
in a subtype independent manner (relapse patients, hazard ratio
= 1.28, P < 8 × 10-3; all patients, hazard ratio = 1.45, P < 6.7
× 10-7). Moreover, YB-1 was superior to estrogen receptor and
HER-2 as a prognostic marker for relapse and survival. For a
subset of patients who were originally considered low risk and
were therefore not given chemotherapy, YB-1 was indicative of
poor survival (P < 7.1 × 10 -17). Likewise, YB-1 was predictive
of decreased BCSS in tamoxifen-treated patients (P = 0.001);
in this setting a Cox regression model once again demonstrated
it to be an independent biomarker indicating poor survival
(hazard ratio = 1.70, P = 0.022).
Conclusions Expression of YB-1 universally identifies patients
at high risk across all breast cancer subtypes and in situations
where more aggressive treatment may be needed. We therefore
propose that YB-1 may re-define high-risk breast cancer and
thereby create opportunities for individualized therapy.
Introduction
The overall goal of predictive oncology is to refine treatment
options for patients such that they may receive optimal care
without experiencing unnecessary side effects. One of the
BCSS: breast cancer specific survival; CI: confidence interval; EGFR: epidermal growth factor receptor; ER: estrogen receptor; HER: human epider-
mal growth factor receptor; HR: hazard ratio; RT-PCR: reverse transcription polymerase chain reaction; PR: progesterone receptor; RFS: relapse free 
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greatest challenges is the identification and implementation of
biomarkers for cancer [1]. Although the antigen Ki67 is report-
edly associated with poor survival it is no longer recom-
mended as a biomarker in prognostic groups, according to a
recent report from the American Society for Clinical Oncology
[2]. Furthermore, this touted biomarker was disappointingly
notpredictive of response to adjuvant chemoendocrine ther-
apy in a study of about 2,000 patients enrolled in two rand-
omized International Breast Cancer Study Group trials [3].
Many reports have shown that human epidermal growth factor
receptor (HER)-2 is a marker of poor prognosis in breast can-
cer, following its initial report in 1987 by Slamon and cowork-
ers [4]. This subsequently led to the development of targeted
agents against it. However, where it is most clinically useful is
as a predictive marker used to guide treatment decisions
about whether to use agents that target this receptor such as
trastuzumab [3]. In fact, HER-2 is no longer recommended as
a prognostic factor in breast cancer [3]. In contrast to HER-2,
the estrogen receptor (ER) is associated with good prognosis
[5,6]. ER is similar to HER-2 in that many therapies targeted
against it have been developed. As such, ER is more routinely
used as a biomarker to guide treatment decisions about
whether hormone therapy is appropriate [3]. Although HER-2
and ER have been very informative for our understanding of
patient survival, and this has lead to the eventual development
of targeted agents, they do not apply to all tumor typesGiven
the limited number of robust biomarkers that predict poor over-
all survival, the question of which should be used to guide
patient care remains open [7]. Breast cancers have been sub-
divided into four subtypes, namely luminal A, luminal B, HER-
2, and basal-like (also called triple negative), based on gene
expression signature [8]. The latter two types are typically
more aggressive than the former two. It should be noted that a
biomarker denoting poor survival across subtypes is yet to be
identified.
Y-box binding protein-1 (YB-1) is a transcription and transla-
tion factor that can promote tumor growth and chemotherapy
resistance by inducing growth-promoting genes such as HER-
2 and EGFR (epidermal grwoth factor receptor) [9], PCNA
(proliferating cell nuclear antigen) [10], MDR-1/ABCA1
(multi-drug resistance-1) [11], cyclin A [12], and cyclin B [12].
YB-1 (also known as nuclease sensitive protein-1 or NSEP-1)
was reportedly expressed in a high-risk group of patients with
BRCA1 mutations by cDNA microarray [13]. Perou and Sorlie
also identified it by microarray analysis [8], but at the transcript
level YB-1 clustered into a unique group of genes, the signifi-
cance of which awaits further description. Perhaps this signa-
ture represents genes that are commonly over-expressed in
breast cancer but do not to fall into a given subtype. With
regard to tumor progression, targeted expression of YB-1 in
the mammary gland under the WAP promoter leads to the
development of tumors; 100% of mice develop invasive carci-
nomas within 52 months [14].
These studies indicate that YB-1 is indeed an oncogene that
is important in the genesis of the disease [14]. In models of
human breast cancer, inhibition of YB-1 with a dominant neg-
ative mutant (interferes with the DNA binding activity of the
protein [S102A]) slows tumor cell growth [15], and this is
associated with the downregulation of EGFR and HER-2 [9].
It thus appears that YB-1 is important in the development of
mammary tumors and that human breast cancer cells not only
express this oncoprotein but also continue to depend upon it
for sustained growth and survival.
It is unclear whether YB-1 carries prognostic value for specific
types of breast cancer or whether it may be a useful biomarker
across all types. In a pilot study, we reported that YB-1 expres-
sion is associated with poor overall survival in a group of 490
patients with invasive breast cancer [9]. In that cohort we also
found that YB-1 was expressed in more than 70% of basal-like
breast cancers [16], but these studies were limited by inade-
quate size to determine patient survival within individual sub-
types. We also lacked the power to evaluate the important
question of whether YB-1 expression is associated with higher
rates of relapse. To address these issues, we screened a large
tissue microarray (TMA) series consisting of 4,049 invasive
breast cancers with 20 years of clinical follow up. The potential
value of YB-1 as a biomarker for aggressive disease was also
examined in a subset of women who were originally consid-
ered to be at low risk and therefore did not receive chemother-
apy. Finally, we examined the possibility that YB-1 may be
associated with more aggressive disease in an adjuvant set-
ting in which tamoxifen was given for 5 years.
Materials and methods
The study cohort and construction of the TMAs used in the
present study has previously been described [5,17]. Sections
from were cut at 4 μm and immunostained with a rabbit poly-
clonal anti-YB-1 antibody (1:1,400; a gift from Dr Colleen Nel-
son, University of British Columbia, Vancouver, BC, Canada).
Of note, this antibody detects marked YB-1 expression in the
cytoplasm of formalin-fixed paraffin-embedded tissues, but
identification of YB-1 in the nucleus is much lower than one
would expect. We believe that this is because the carboxyl-ter-
minal epitope is somehow masked during fixation, as we pre-
viously reported [9].
The immunohistochemical staining was performed using an
Automated Secondary System (cat #760-4205; Ventana,
Tucson, AZ, USA). Slides were stained concurrently for ER,
HER-2, and progesterone receptor (PR) using standard immu-
noperoxidase techniques, as described previously [5,17].
Breast cancer subtypes were determined using immunohisto-
chemical markers (HER-2, ER, and PR) to define each type.
Subtype definitions were as follows: luminal A (ER-positive
and/or PR positive, HER-2 negative), luminal B (ER positive
and/or PR positive, HER-2 positive), triple negative (ER nega-
tive, PR negative, HER-2 negative) [18], HER-2 positive (ERAvailable online http://breast-cancer-research.com/content/10/5/R86
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negative, PR negative, HER-2 positive), and unassigned (miss-
ing data on any of the three markers). TMAs were evaluated
independently by two pathologists (Drs Hamid Masoudi and
Dimithry Turbin) to quantify the percentage of tumor cells
staining positive for YB-1, ER, and PR as follows: negative
(<1%), positive 1+ (1% to 25%), positive 2+ (25% to 75%),
or positive 3+ (>75%). For the analyses, YB-1 expression was
dichotomized into 0 or 1 (where 0 = negative or very low, and
1 = moderate to high [2+ and 3+]). HER-2 was considered
positive if it was 3+, as we previously described [9]. Of the
4,049 samples, for 3,097 YB-1 could be scored and breast
cancer specific survival (BCSS) outcome data were available
for these. In addition, in 1,201 cases that could be scored for
YB-1, data were available regarding relapse free survival
(RFS). Immunohistochemical data was collected for samples
that were blinded as to clinical outcomes.
Statistical analyses were performed using SPSS software ver-
sion 13.0 (SPSS Inc., Chicago, IL, USA) and were described
previously [5]. Briefly, for univariate analyses, BCSS and RFS
were estimated using Kaplan-Meier curves. Differences in sur-
vival were determined using Breslow tests. For BCSS, survival
time was censored at death if the cause was not breast cancer
or if the patient was still alive at the end of the study. Six
patients with unknown cause of death were excluded from the
BCSS analysis. In addition, RFS was also censored at death if
the cause was not breast cancer and if the patients were alive
without any relapse at the end the study. For multivariate anal-
yses, Cox proportional hazards models were used to calculate
adjusted hazard ratios (HRs), accounting for independent cov-
ariates. A likelihood ratio was used to determine the extent of
association of YB-1 expression with particular subtypes.
Spearman's correlation was also used to determine the extent
of correlation between YB-1 expression and other markers
such as ER.
Results and discussion
YB-1 was detected by immunostaining in 41% (1,644/4,049)
of the patient samples, in which it was highly predictive of
decreased RFS (P < 2.5 × 10-20). We observed that 80% of
patients who expressed little or no YB-1 were relapse free
over 5 years, as compared to 60% if the protein was highly
expressed (Figure 1a). Consistent with this observation, YB-1
was associated with poor overall BCSS (P < 7.3 × 10-26; Fig-
ure 1b). Among patents expressing low levels of YB-1, about
90% were alive after 5 years, as compared with only 75% of
those who expressed YB-1 (Figure 1b). Furthermore, this was
the case whether patients were node positive or node nega-
tive (Additional file 1). Specifically, YB-1 was expressed in
33% of node-negative breast cancer patients, in whom it was
associated with poor survival (P = 1.0 × 10-13). It was similarly
expressed in 37% of node-positive patients, in whom it once
again predicted poor survival (P = 3.6 × 10-14).
Of note, patients whose tumors expressed YB-1 tended to be
younger (r = -0.203, P = 6.512 × 10-17), their tumors were of
higher grade (r = 0.268, P = 2.957 × 10-27), and many were
ER negative (r = -0.343, P = 5.452 × 10-47; Additional file 2).
There was also a positive correlation with tumors harboring
amplified HER-2 (r = 0.217, P = 8.588 × 10-19; Additional file
2) corroborating smaller reports by us [9] and others [19], in
which cohorts of 490 and 73 patients were evaluated,
respectively.
Importantly, YB-1 staining was consistently associated with
disease recurrence, independent of breast cancer subtype as
defined by ER, PR, and HER-2 expression (Figure 2: luminal A,
P = 3.04 × 10-8; luminal B, P = 0.133; triple negative, P = 1.9
× 10-2; HER-2, P = 2.7 × 10-2). An exception was found in the
luminal B cohort, and the lack of significance was possibly
because there were only 86 patients in this subgroup and so
the analysis was under-powered. Taking our observations fur-
ther, BCSS was shorter when YB-1 was higher in all breast
cancer subtypes (Figure 3: luminal A, P = 2.8 × 10-9; luminal
B, P = 0.034; triple negative, P = 7 × 10-3; HER-2, P = 1.6 ×
10-2). Of note is the observation that although YB-1 is
expressed less frequently in the luminal A subtype, its expres-
sion was the most significant, probably because this consti-
tuted the largest group of patients overall. Whether YB-1
cooperates with estrogen to promote the growth of luminal A
breast cancer is not known and is a question that we are
actively addressing. To evaluate further the significance of YB-
1 as a prognostic factor across breast cancer subtypes, we
conducted Cox regression analyses and confirmed that it inde-
pendently predicted RFS (HR = 1.284, 95% confidence inter-
val [CI] = 1.068 to 1.544; P = 8 × 10-3) and BCSS (HR =
1.452, 95% CI = 1.253 to 1.682; P = 6.74 × 10-7; Additional
files 3 and 4).
These findings prompted us to examine how YB-1 compared
with established prognostic factors used to guide patient diag-
nosis and thus treatment. Importantly, YB-1 was more indica-
tive of RFS (HR = 1.331, 95% CI = 1.169–1.516; P = 1.61
× 10-5) than HER-2 (HR = 1.256, 95% CI = 1.066 to 1.479;
P = 6.0 × 10-3) or ER (HR = 0.942, 95% CI = 0.816 to 1.087;
P = 4.13; Table 1). Similarly, YB-1 expression posed an even
greater risk for reduced BCSS (HR = 1.456, 95% CI = 1.257
to 1.656; P = 5.6 × 10-7) than did HER-2 expression (HR =
1.259, 95% CI = 1.052 to 1.506; P = 1.2 × 10-2) or ER status
(HR = 0.816, 95% CI = 0.720 to 0.991; P = 0.038; Table 2).
Moreover, YB-1 was also better at predicting outcome than
tumor grade (HR = 1.416, 95% CI = 1.215 to 1.651; P = 8.9
× 10-6) or patient age (HR = 1.160, 95% CI = 1.000 to 1.345;
P = 5 × 10-2). We therefore conclude that YB-1 expression
can be used to identify those patients who are likely to require
more aggressive therapy, given its pronounced association
with markedly reduced RFS and attenuated BCSS.Breast Cancer Research    Vol 10 No 5    Habibi et al.
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Figure 1
YB-1 expression is associated with relapse and poor survival in the entire cohort YB-1 expression is associated with relapse and poor survival in the entire cohort. (a) Out of a total of 1,201 patients, YB-1 was expressed in 41% 
(495/1201) with recurrent breast cancer. YB-1 expression was associated with shorter relapse free survival. 'N' represents the number of patients 
who had breast cancer recurrence (number of events). (b) The expression of YB-1 is associated with a significant increase in breast cancer specific 
deaths (BCSS). YB-1 was expressed in 35% (1,081/3,097) of patients with reduced BCSS. Patient survival was based on deaths specifically 
related to breast cancer and not other causes. BCSS = breast cancer specific survival; YB-1 = Y-box binding protein-1.
Figure 2
YB-1 is linked to relapse in all subtypes of breast cancer defined by hormone receptors and HER-2 status YB-1 is linked to relapse in all subtypes of breast cancer defined by hormone receptors and HER-2 status. Tumor tissue microarrays were stained for 
YB-1, ER, PR, and HER-2 (n = 2,978 cases in total for all markers). The relative distribution of YB-1 was evaluated in breast cancer subtypes. In all 
subtypes, the expression of YB-1 was associated with shorter relapse free survival. 'N' represents the number of YB-1 positive patients who had 
breast cancer relapse (number of events) in each subtype. ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone 
receptor; YB-1, Y-box binding protein-1.Available online http://breast-cancer-research.com/content/10/5/R86
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As breast cancer is being diagnosed earlier, there is a need to
identify those individuals who may or may not need chemother-
apy. Patients who have grade I to II tumors with no evidence
for lymph node involvement (T1N0) have been categorized as
being in a low-risk group, in which the odds of survival should
be very good. Within the TMA we analyzed, there were 1,292
cases considered to be low risk. However, if these patients
had tumors that expressed YB-1 they were more likely to die
from breast cancer (Figure 4). We found that 437 out of 1,292
(34%) cases expressed YB-1, indicating that a significant pro-
portion of patients considered to be at low risk were more
likely to die from the disease than expected, suggesting that
more aggressive treatment might have improved their out-
come. Using 5-year survival as a benchmark, we found that
more than 95% of patients were alive if YB-1 was not highly
expressed. However, if YB-1 expression was high then only
75% of patients were alive at 5 years (Figure 4; P = 7.09 × 10-
17). By multivariate analysis, YB-1 expression was a significant
adverse prognostic biomarker in patients who did not receive
chemotherapy (HR = 1.898, 95% CI = 1.460 to 2.465; P <
1.67 × 10-6; Additional file 5). Again, it was better at predicting
BCSS than HER-2 or ER (Additional file 5).
To further this line of investigation, we addressed whether YB-
1 emerged as a prognostic marker in patients taking tamoxifen.
In a nested cohort of ER-positive breast cancer patients
treated with tamoxifen (n = 671), YB-1 expression was asso-
ciated with reduced BCSS (Figure 5). Of note, YB-1 was
expressed in 185 out of 671 cases (28%), indicating that
expression of this protein is not an uncommon event in these
tumors. We chose to evaluate this within a 5-year time-frame,
given that this is the typical duration of tamoxifen administra-
Figure 3
YB-1 is associated with BCSS in all subtypes of breast cancer YB-1 is associated with BCSS in all subtypes of breast cancer. YB-1 is expressed in 23.1% (480/2078) of luminal A and 51.6% (95/183) of luminal 
B, and is more likely to be expressed in the ER-negative breast cancers, in which it was found in 64.6% (320/493) and 66.4% (148/223) of TNP 
and HER-2 subtypes, respectively. Its expression is associated with poor survival in all subtypes of breast cancer. 'N' represent of number of YB-1 
positive patients who died from breast cancer (number of events) in each subtype. Examples of the immunostaining are represented in the inset 
(magnification 200×). BCSS, breast cancer specific survival; ER, estrogen receptor; YB-1, Y-box binding protein-1.Breast Cancer Research    Vol 10 No 5    Habibi et al.
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tion. In a Cox regression model, YB-1 (HR = 1.707; P = 2.2 ×
10-2) was independently associated with a greater risk for
breast cancer related death (Additional file 6). Thus, in the
adjuvant setting, YB-1 can also serve as a useful biomarker of
aggressive disease. It would therefore be interesting to evalu-
ate YB-1 within the context of more contemporary standard-of-
care hormone therapies such as raloxifene, letrozole, anastro-
zole, and exemestane.
Our data indicate that YB-1 is a strong prognostic marker for
all subtypes of human breast cancer, even in cases that were
thought to be low risk and therefore did not need chemother-
apy. We also extend preliminary clinical data from others sug-
gesting that YB-1 expression distinguish a high-risk group of
breast cancer patients. Notably, Janz and coworkers [20]
observed YB-1 expression in 49% (20/42) of patients receiv-
ing chemotherapy, and there was a trend toward an associa-
tion of YB-1 with poor disease-free survival, although this
finding did not reach statistical significance. The same authors
also examined YB-1 expression in a cohort of 42 low-risk can-
cers not treated with chemotherapy and found that it was
expressed in 76% (32/42) of those cases. Notably, none of
the patients who had low YB-1 expression relapsed, whereas
30% of those with high levels did (P < 1.1 × 10-2). In addition,
Huang and colleagues [21], in a study of 42 patients, reported
that YB-1 was associated with recurrence after adjuvant
chemotherapy, although long-term outcomes were not evalu-
ated. We now provide definitive retrospective data that indi-
cate that YB-1 expression in low-risk patients is strongly
associated with a higher rate of breast cancer related deaths.
Importantly, YB-1 was a significant factor in a Cox regression
model when other variables that typically define risk were
taken into consideration. Taking these analyses together with
the prognostic value of YB-1 identified in the present study,
YB-1 was comparable to tumor size and was superior to HER-
2, ER, patient age, or tumor grade as a prognostic marker for
RFS and BCSS in the majority of analyses.
During the past few years, several new approaches have been
proposed to identify patients at high risk. For example, diag-
nostic tests have been developed to stratify patients based on
gene expression and are currently being prospectively evalu-
ated. The first test, Mammaprint®, stratifies node-negative
breast cancer patients based on a set of 70 genes using
Table 1
In a multivariate analysis of recurrent breast cancer cases, the 
expression of YB-1 was better than HER-2 or ER in predicting 
events
Prognostic marker Patients with relapse
HR (95% CI) P value
Nodal status
Positive versus negative 1.951 (1.725 to 2.206) 1.7 × 10-26
Tumor size (cm)
2 to 5 1.392 (1.227 to 1.579) 2.8 × 10-7
>5 1.921 (1.227 to 2.445) 1.2 × 10-7
Grade
III versus II versus I 1.300 (1.139 to 1.482) 9.6 × 10-5
Age (years)
<50 versus ≥ 50 1.000 (0.878 to 1.139) 1.000
ER
Positive versus negative 0.942 (0.816 to 1.087) 0.41
HER-2
Positive versus negative 1.256 (1.066 to 1.479) 6.0 × 10-3
YB-1
Positive versus negative 1.331 (1.169 to 1.516) 1.6 × 10-5
The predictive power of YB-1 was similar to that of tumor grade and 
smaller tumor size, but not as great as that of nodal status. CI, 
confidence interval; ER, estrogen receptor; HER, human epidermal 
growth factor receptor; HR, hazard ratio; YB-1 = Y-box binding 
protein-1.
Table 2
In a multivariate analysis of breast cancer cases, the 
expression of YB-1 was better than HER-2 or ER in predicting 
reduced BCSS
Prognostic marker Patients with reduced BCSS
HR (95% CI) P value
Nodal status
Positive versus negative 2.405 (2.083 to 2.776) 4.6 × 10-33
Tumor size (cm)
2 to 5 1.605 (1.387 to 1.859) 2.8 × 10-10
>5 2.269 (1.749 to 2.943) 2.8 × 10-10
Grade
III versus II versus I 1.416 (1.215 to 1.651) 8.9 × 10-6
Age (years)
<50 versus = 50 1.160 (1.000 to 1.345) 5.0 × 10-2
ER
Positive versus negative 0.816 (0.720 to 0.991) 3.8 × 10-2
Her-2
Positive versus negative 1.259 (1.052 to 1.506) 1.2 × 10-2
YB-1
Positive versus negative 1.456 (1.257 to 1.656) 5.6 × 10-7
YB-1 was approximately equal to the power of tumor grade yet not 
as accurate as tumor size or nodal status in predicting reduced 
BCSS. BCSS, breast cancer specific survival; CI, confidence 
interval; ER, estrogen receptor; HER, human epidermal growth factor 
receptor; HR, hazard ratio; YB-1 = Y-box binding protein-1.Available online http://breast-cancer-research.com/content/10/5/R86
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cDNA microarrays [22,23]. A quantitative PCR-based
method, Oncotype Dx®, is commercially available and appears
to define a group of low-risk patients who may be able to avoid
chemotherapy [24]. This test was designed to amplify a cas-
sette of 21 genes (16 target genes and five housekeeping
genes). Interestingly, within this cassette there are two known
YB-1 target genes, namely cyclin B and HER-2. Furthermore,
the assay is designed to detect Ki67, which is associated with
higher levels of YB-1 [9].
Because YB-1 is expressed in 30% of node-negative breast
cancers, based on the data presented herein, it may be useful
in stratifying patients thought to be at low risk. We propose
that YB-1 could be monitored either using quantitative RT-
PCR or in a low-cost manner using immunohistochemistry, just
as HER-2 and ER proteins are currently evaluated clinically.
We have already optimized the detection of YB-1 using quan-
titative RT-PCR, as described previously [9], and by immunos-
taining using an automated system described herein. Thus,
this novel biomarker could easily be translated into routine clin-
ical practice for diagnostic purposes. Perhaps YB-1 may serve
to define further breast cancer subtypes in general, because
we are now beginning to appreciate that triple negative breast
cancers can be further divided into five subcategories [18].
Thus, YB-1 can be added to define high-risk patients within
the triple negative subtype, as was recently reported for EGFR
[25]. Finally, the degree to which the nuclear localization of
YB-1 contributes to the aggressiveness of breast cancers
continues to be of great interest to us, given its established
role as an oncogenic transcription factor. Additional studies
will be required, with antibodies that detect nuclear YB-1, to
shed light on this.
Although we found that YB-1 is expressed in about 40% of
invasive breast carcinomas, the underlying reason for this is
unknown. Evidence thus far indicates that YB-1 is not com-
monly amplified, based on analyses of primary tumors [16] and
breast cancer cell lines [26]. There are reports indicating that
GATA-1 binds to the YB-1 promoter and suppresses its
expression during erythrocyte differentiation [27]. Under
stress induced by cisplatin c-myc can also bind to E-boxes
located at several sites along the YB-1 promoter [28].
Although stress can induce YB-1, it is still curious to us that
breast cancer cell lines express high levels under normal
growth conditions, and patients have high levels before chem-
otherapy or radiation because the tumors from that were under
investigation in this report were obtained prior to treatment. To
begin to elucidate the regulation of YB-1, we examined its pro-
moter for potential regulatory elements using CONSITE (a pre-
dictive algorithm that mitigates against false positives) [29].
Using a 100% stringency criterion, we found that across spe-
cies the YB-1 promoter has n-myc and snail binding sites [29].
Furthermore, we identified additional regulatory sites on the
YB-1 promoter, such as hunchback, rel, sox, and myf [29].
Although n-myc is not thought to play a central role in breast
cancer, c-myc does play a role [30], and they both bind to E-
boxes. Our virtual screen is consistent with the initial charac-
terization of the YB-1 promoter, in which six E-boxes were
identified [31]; this may explain why c-myc reportedly induces
its expression in cooperation with p73 [28]. More recently,
twist – which also binds to E-boxes – was reported to induce
Figure 4
YB-1 is a high risk factor in low-risk patients YB-1 is a high risk factor in low-risk patients. YB-1 is expressed in 34% 
(437/1292) of low-risk patients who received no systemic therapy. 'N' 
represents the number of patients who died from breast cancer 
(number of events) in each category. Survival was stratified based on 
whether tumors expressed YB-1 (light grey line) or did not (black line). 
YB-1, Y-box binding protein-1.
Figure 5
In the adjuvant setting expression of YB-1 is indicative of reduced  BCSS In the adjuvant setting expression of YB-1 is indicative of reduced 
BCSS. YB-1 expression was evaluated in a nested cohort of 671 
tamoxifen-treated patients. Twenty-eight percent of patients expressed 
YB-1 (185/671), in whom its expression was associated with reduced 
BCSS. Survival was assessed over 5 years, because this is the stand-
ard duration of tamoxifen administration. ER, estrogen receptor; YB-1, 
Y-box binding protein-1.Breast Cancer Research    Vol 10 No 5    Habibi et al.
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YB-1 [32]. To date, this is the only study addressing the regu-
lation of YB-1 expression specifically in breast cancer.
Conclusions
The present data provide new impetus to translate these labo-
ratory findings into routine clinical practice, given the remarka-
ble strength of YB-1 as a biomarker for aggressive breast
cancer across all subtypes. We anticipate that this new
biomarker will create better opportunities to individualize ther-
apy and may ultimately be developed as a novel molecular
target.
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